The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally. The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
Research in the Division of Structural Biology is aimed at understanding the structural basis for the function and regulation of proteins and protein complexes implicated in cancer. Our research programmes are complemented by close collaborations with other groups elsewhere in the Institute, including groups from the Divisions of Cancer Biology and Cancer Therapeutics, and provide the mechanistic and structural framework for developing new therapeutics targeting cancer. The Division of Structural Biology is well equipped with state of the art in-house X-ray equipment and robotics, computational infrastructure, an in-house electron microscopy facility (including a high-end 200keV microscope equipped with a direct electron camera and Volta phase plate to be installed in 2019) and has direct access to a 300 keV Krios microiscope, as part of the LonCEM consortium.
A position to manage the Structural Biology Platform is available in the Division of Structural Biology (ref 620). The Structural Biology Platform manager will be directly responsible for the smooth operation of the Division’s crystallisation infrastructure, including in-house X-ray crystallography equipment and will also be involved in the development and maintenance of the EM facility together with other existing staff members. The post holder will coordinate the EM, crystallographic and SAXS data collection experiments at synchrotron radiation sources and Block Allocation Group (BAG) beam time applications, and the training of new staff and PhD-students. In addition, the post holder will be responsible for the maintenance and running of the biophysical equipment of the Division.
Applicants must have a PhD in a biological or physical science, and experience in macromolecular crystallography (to include, protein crystallisation, & protein crystallography) and have considerable postdoctoral experience. Experience in molecular biology, biophysics, an/or electron microscopy will be an advantage.
The starting salary for the position will be in the range £42,792 to £50,943 p.a. inclusive (based on previous experience) and the post is non time limited. Informal enquiries to Laurence.email@example.com or Rob.firstname.lastname@example.org.
Please DO NOT send your application to Laurence Pearl or Rob van Montfort, but apply via the e-recruitment system on our website www.icr.ac.uk. Closing date: 10th February 2019
The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP.
This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.
To unsubscribe from the CCP4BB list, click the following link: